Brio Pharma

BRIO PHARMA

As a Japanese subsidiary of OHSONG PHARM Co., Ltd., we provide integrated solutions to help healthcare products enter the Japanese market.

  • Japan MAH Holder(MAH Type l, ll)

    • JMDF ICC
    • GQP / GVP
    • Consulting
    • Regulatory affairs
    • Medical Device(Type 2)
  • Japan Medical Device Holder(MAH Type ll)

    • GQP / GVP
    • Consulting
    • Regulatory affairs
BRIO PHARMA PeRFORMANCE (IN JAPAN)
2022, Ibandronate (PFS) approval obtained
2024, Escitalopram (Tablet) approval obtained